Icure Pharmaceutical Incorporation (KOSDAQ:175250)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,170.00
+231.00 (11.91%)
At close: Aug 5, 2025

KOSDAQ:175250 Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
93,44583,38550,70556,80659,36764,283
Revenue Growth
64.23%64.45%-10.74%-4.31%-7.65%-28.69%
Gross Profit
4,4514,3986,6411,298-5,580-4,804
Operating Income
-15,681-18,333-15,969-27,605-27,087-30,119
Net Income
-31,869-33,6001,198-31,272-41,766-38,167
Earnings Per Share
-851.45-897.4532.00-837.00-1793.00-1763.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,93311,01022,4378,55853,78624,417
Total Debt
25,72627,65540,44074,01587,00974,186
Net Cash (Debt)
-21,793-16,645-18,003-65,457-33,224-49,769
Net Cash Growth
------
Net Cash Per Share
-582.07-444.58-481.04-1742.81-1426.23-2298.37

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-3,638-2,685-17,054-13,519-11,282-26,228
Capital Expenditures
-3,721-5,110-2,023-2,225-4,197-5,701
Free Cash Flow
-7,359-7,795-19,077-15,744-15,479-31,929
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
4.76%5.27%13.10%2.28%-9.40%-7.47%
Operating Margin
-16.78%-21.99%-31.49%-48.59%-45.63%-46.85%
Pretax Margin
-35.85%-42.34%6.89%-57.00%-72.58%-60.41%
Profit Margin
-34.10%-40.29%2.36%-55.05%-70.35%-59.37%
FCF Margin
-7.88%-9.35%-37.62%-27.72%-26.07%-49.67%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--56.63---
Forward PE
-7.877.877.877.877.87
PS Ratio
0.870.971.341.381.345.27